Does Omeprazole Cause Cancer? Long-Term Stomach Cancer Risk

Omeprazole has not been proven to cause cancer in humans, but decades of observational research have turned up statistical associations between long-term use and several cancer types, most prominently stomach cancer. Those associations look alarming at first glance but are smaller and less certain than headlines suggest, largely because the studies behind them struggle to separate the drug’s effects from the diseases it treats. The story is more nuanced than a yes-or-no answer allows, and for one cancer type, omeprazole appears to be protective.

Where the Cancer Worry Began

The concern dates to the late 1980s, before omeprazole was even approved for widespread use. In rodent studies, long-term dosing produced tumors called carcinoid growths in the stomach lining. The mechanism was straightforward: omeprazole suppresses stomach acid so effectively that the body responds by ramping up production of gastrin, a hormone that stimulates acid-producing cells. In rats, chronically elevated gastrin drove a specific cell type in the stomach wall, called the enterochromaffin-like (ECL) cell, to multiply at an accelerated rate. That unchecked multiplication eventually led to tumors.¹ Early rat experiments confirmed that omeprazole treatment doubled plasma gastrin levels within days and pushed ECL cells into rapid self-replication, with cell density climbing steadily from the ninth day onward.²

The leap from rat stomach to human stomach is not automatic. Rats are far more sensitive to gastrin-driven ECL cell growth than humans are. But the biological plausibility kept the question alive: if chronic acid suppression raises gastrin, and gastrin promotes cell growth in the stomach lining, could years of omeprazole use nudge a human stomach toward cancer? Experimental data supports a chain running from gastrin to ECL cell hyperplasia, to dysplasia, and eventually to neoplasia, at least in laboratory models.³ That chain became the theoretical scaffold for dozens of human studies over the next three decades.

The Gastric Cancer Signal in Human Studies

Multiple large observational studies have found that people who use proton pump inhibitors (PPIs) like omeprazole for extended periods develop stomach cancer at higher rates than people who do not. A pooled analysis of 13 observational studies estimated that PPI users had roughly 80% higher risk of gastric cancer compared with non-users, with the association growing stronger past three years of use.⁴ A Swedish population-based cohort study pegged the increase at about 45% compared with people taking a different class of acid-reducing drug, H2 receptor antagonists. That study also found the risk climbed with longer use and higher cumulative doses, though the absolute risk remained low: roughly one extra case of gastric cancer for every 2,100 patients treated over five years.⁵

A Hong Kong study of about 63,000 patients treated for H. pylori infection found that those who continued using PPIs for more than three years had roughly double the risk of gastric cancer compared with people who never used them.⁶ These numbers sound frightening in isolation, but they need to be read alongside a critical limitation that runs through nearly all of this evidence.

The Confounding Problem That Haunts Every Study

Omeprazole is prescribed to people with stomach problems. Stomach problems are themselves risk factors for stomach cancer. This creates a tangle that epidemiologists call confounding by indication and protopathic bias: the drug gets blamed for an outcome that was already more likely in the people who needed the drug in the first place. Someone experiencing early, undiagnosed stomach cancer may visit a doctor complaining of reflux or pain, get prescribed omeprazole, and later be diagnosed with the cancer that was already developing before they ever took a pill.

A large matched case-control study published in PLOS Medicine tested this directly. Without adjusting for symptom-related diagnoses, omeprazole use appeared to more than double the odds of upper gastrointestinal cancer. But when researchers excluded PPI use in the final year before diagnosis and adjusted for the stomach symptoms that originally prompted prescribing, the association vanished. In fact, remote use of omeprazole, more than three years before diagnosis, was associated with lower odds of upper GI cancer.⁷

A separate pooled analysis from the Stomach Cancer Pooling Project reached a similar conclusion from a different angle: the association between PPI intake and gastric cancer was strongest for short durations of use and disappeared with longer exposure. The researchers noted that this pattern is the opposite of what you would expect from a true carcinogen, where risk should climb with more exposure. Instead, the pattern is consistent with protopathic bias, where the apparent association is driven by people who started PPIs because of symptoms caused by a cancer already underway.⁸ This does not mean long-term PPI use is guaranteed harmless, but it does mean the alarming-sounding risk ratios from observational studies deserve a heavy asterisk.

The H. Pylori Complication

Helicobacter pylori, the bacterium that causes most stomach ulcers and is itself a major risk factor for gastric cancer, adds another layer of complexity. Many people prescribed omeprazole have current or past H. pylori infections. One influential Hong Kong study followed patients who had already been successfully treated for H. pylori and found that those who continued using PPIs still had an elevated risk of stomach cancer, with the hazard ratio climbing from about 2.4 for any PPI use to over 8 for use lasting three or more years. The absolute risk difference, though, was about four extra cases per 10,000 person-years of PPI use.⁹

That same research group found an interesting wrinkle: among patients who took aspirin alongside their PPI, the elevated cancer risk disappeared, while the risk in non-aspirin users appeared even higher.¹⁰ Aspirin has known anti-cancer properties through separate pathways, so this finding is biologically plausible, but it also illustrates how many overlapping variables these studies need to untangle. The broader point is that PPIs and H. pylori may interact: when PPI use continues for years alongside ongoing or past infection, the combination may act synergistically on the stomach lining in ways that exceed either factor alone.¹¹

Beyond the Stomach

Gastric cancer gets the most attention, but researchers have also looked at colorectal, pancreatic, and liver cancer in PPI users. The picture varies by cancer type, and none of the associations are as strong or consistent as the gastric data.

For colorectal cancer, a systematic review concluded that current evidence does not support a causal link with PPI use overall.¹² A large population-based cohort study found no increased risk with PPI use in general, but did find a modest signal with prolonged use: risk appeared to rise after about two years and was roughly 60% higher for people using PPIs for four or more years.¹³ A separate Taiwanese population-based study reported a stronger dose-dependent association, with risk climbing steeply at the highest PPI doses.¹⁴ These studies disagree on magnitude, and the same confounding issues that plague the gastric cancer literature apply here too.

For pancreatic cancer, a French nationwide case-control study found a small increase in risk with PPI use after adjusting for confounders, on the order of 5% for any use, but climbing to roughly 17-18% at the highest cumulative doses.¹⁵ An earlier study also found higher risk among PPI users with longer cumulative exposure, after adjusting for smoking, diabetes, and other known pancreatic cancer risk factors.¹⁶ Both of these are observational and susceptible to the same confounding caveats.

For liver cancer, a meta-analysis of studies in patients with chronic liver disease found that PPI users had about 67% higher risk of developing hepatocellular carcinoma compared with non-users.¹⁷ One proposed mechanism involves PPI-driven changes in gut bacteria that promote liver inflammation.¹⁸ But the study populations already had chronic liver disease, a major cancer risk factor in its own right, so disentangling the drug’s contribution from the underlying disease is difficult.

Where PPIs May Protect Against Cancer

Not all the cancer data points in the same direction. For esophageal adenocarcinoma, the cancer that can develop from Barrett’s esophagus (a complication of chronic acid reflux), PPI use appears to be protective. A meta-analysis of observational studies found that PPI use was associated with a roughly 71% reduction in risk of esophageal adenocarcinoma or high-grade precancerous changes in Barrett’s patients. The protective effect appeared stronger with longer use, and none of the included studies found PPIs increased risk.¹⁹

A study in US male veterans with Barrett’s esophagus found PPI use was associated with about 41% lower odds of esophageal adenocarcinoma. High-dose PPIs showed an even larger protective effect.²⁰ A separate meta-analysis of all gastric acid suppressants and esophageal adenocarcinoma risk found no statistically significant association in either direction, consistent with the idea that PPIs are at minimum not increasing risk for this cancer.²¹

This is a genuinely important counterpoint. For people with Barrett’s esophagus, a condition that itself carries significant cancer risk, PPIs are recommended precisely because acid suppression appears to slow or prevent the progression toward malignancy. Stopping PPIs in these patients out of fear of a different cancer could paradoxically increase their overall cancer risk.

The Nitrosamine Pathway and Gut Bacteria

Acid suppression changes the stomach’s internal environment in ways that go beyond gastrin. When stomach acid drops, bacteria that normally cannot survive in the stomach begin to thrive. Some of those bacteria convert nitrates from food into nitrites and N-nitroso compounds, which are known carcinogens. Short-term omeprazole treatment in healthy volunteers produced significant increases in bacterial counts and N-nitrosamine concentrations in gastric juice.²²

Long-term data complicates this picture. A study of patients on long-term omeprazole did not find elevated nitrite or nitrosamine levels inside the stomach itself, but did find increased urinary excretion of N-nitrosamines, suggesting the compounds were being formed and absorbed elsewhere in the body. The effect appeared more pronounced in patients with H. pylori infection.²³ Whether this level of nitrosamine exposure is enough to meaningfully raise cancer risk in a human over a lifetime is genuinely unknown. It is a plausible mechanism, not a proven cause.

Why Your Genetics Might Matter

Not everyone metabolizes omeprazole at the same rate. The drug is broken down primarily by a liver enzyme called CYP2C19, and genetic variations in this enzyme create dramatically different drug exposures between individuals. People who metabolize the drug slowly (sometimes called “poor metabolizers”) end up with blood levels of omeprazole that can be roughly 20 times higher than those of fast metabolizers on the same dose.²⁴

Those higher drug levels translate to more acid suppression, higher gastrin levels, and greater changes to the stomach lining. Patients with one or two copies of the slow-metabolizing gene variant who take long-term omeprazole show significantly elevated markers of gastric mucosal change compared with fast metabolizers on the same regimen.²⁵ About 2-5% of people of European ancestry and up to 15-20% of people of East Asian ancestry are poor metabolizers. This variation means the theoretical cancer risk from long-term omeprazole use is not evenly distributed across the population, though no study has yet shown that poor metabolizers actually develop cancer at higher rates. It is a mechanistic concern, not a demonstrated clinical outcome.

Gastric Neuroendocrine Tumors in Humans

The rodent carcinoid tumors that first raised alarm have a human counterpart, but it looks very different from what the rat data might predict. A retrospective study of 66 gastric neuroendocrine tumors found that tumors arising in long-term PPI users were overwhelmingly small and superficial, with 98% confined to the inner stomach wall layers, compared with 79% in non-PPI users. Not a single long-term PPI user in the study developed distant metastases or died of the tumor during follow-up, compared with three metastatic cases and seven deaths in the control group. PPI-associated tumors had significantly longer overall survival.²⁶

There was one catch: five of the PPI users went on to develop additional neuroendocrine tumors, while none of the non-PPI users did. So while these tumors can recur with ongoing PPI use, they appear to behave in an indolent, non-aggressive manner. This is reassuring in the sense that the worst-case scenario from the rodent data, aggressive gastric carcinoids, does not appear to translate to humans at standard doses.

PPIs Compared with Other Acid Reducers

An analysis of the FDA’s adverse event reporting system compared cancer-related signals between PPIs and H2 receptor antagonists (the older class of acid reducers that includes famotidine). Most PPIs showed more cancer-related adverse event signals than H2 receptor antagonists, with a notable exception: ranitidine, which was pulled from the market in 2020 over its own carcinogen contamination issue, had more cancer signals than any PPI. Setting ranitidine aside, H2 receptor antagonists appeared to carry fewer cancer-related signals than PPIs.²⁷ This kind of signal analysis is useful for generating hypotheses but cannot prove causation, since adverse event reports are voluntary and subject to reporting bias.

Nutrient Absorption and Indirect Risk

Long-term PPI use has been linked to reduced absorption of several vitamins and minerals, including vitamin B12, vitamin C, calcium, iron, and magnesium.²⁸ Some of these nutrients play roles in immune surveillance and cellular repair processes that are relevant to cancer prevention. Whether PPI-driven nutrient depletion meaningfully contributes to cancer risk over decades is speculative at this point, but it represents yet another mechanism by which long-term acid suppression could theoretically influence the body’s cancer defenses. Monitoring nutrient levels during prolonged PPI therapy is already standard advice from most gastroenterology guidelines.

What Clinical Guidelines Actually Recommend

The American Gastroenterological Association published a clinical practice update on de-prescribing PPIs that captures the medical establishment’s current stance. The update emphasizes that every PPI user should have a regular review of whether they still need the drug, and that patients without a clear ongoing indication should be considered for a trial off the medication. Patients on twice-daily dosing should generally try stepping down to once daily.²⁹

But the same guideline is explicit that the decision to stop a PPI should be based on lacking a medical need, not on fear of side effects. Patients with complicated reflux disease, Barrett’s esophagus, eosinophilic esophagitis, or high bleeding risk should generally stay on their PPI. The guideline also warns that stopping long-term PPIs can trigger rebound acid symptoms that are temporary but uncomfortable, and that either gradual tapering or abrupt discontinuation are acceptable approaches.³⁰

Genomic Instability at High Doses

Laboratory studies looking at omeprazole’s direct effects on DNA have found evidence that high doses can cause genomic instability, meaning damage to the structure or replication of chromosomes. A review of toxicogenetic data suggested that long-term omeprazole exposure at doses ranging from 5 to 40 mg per kilogram of body weight could induce these changes in experimental models.³¹ Those are very high doses relative to what humans take (a standard dose is 20 mg total, not per kilogram), so the direct relevance to people taking a daily capsule is uncertain. Still, it adds one more thread to the web of theoretical mechanisms.

The honest summary of where the science stands is that omeprazole has several plausible pathways by which it could promote cancer over many years, including elevated gastrin, altered gut bacteria, nitrosamine formation, nutrient depletion, and possibly direct DNA effects at high concentrations. What the science has not been able to do is cleanly separate these effects from the confounding created by the fact that people who take omeprazole already have stomach conditions that raise cancer risk. The absolute risk remains small by any measure, and for at least one cancer type, PPIs appear to be beneficial. For someone who genuinely needs the drug, the evidence does not support stopping it purely out of cancer fear.